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Evaluation of 5 Novel protein 
biomarkers for the rapid diagnosis 
of pulmonary and extra-pulmonary 
tuberculosis: preliminary results
Amit Singh1,*, Anil Kumar Gupta1,*, Krishnamoorthy Gopinath1,†, Pawan Sharma2,‡ & 
Sarman Singh1
Improved methods are required for the early and accurate diagnosis of tuberculosis, especially in the 
patients with smear-negative disease. Several biomarkers have been tried but most have shown poor 
sensitivity or specificity. In present study we aimed to evaluate the diagnostic utility of five novel 
antigens identified earlier by us. This is an initial study conducted on 250 subjects. The five recombinant 
antigens, named as rSS1 (Rv2145c), rSS2 (Rv0164), rSS3 (Rv1437), rSS4 (Rv1827) and rSS5 (Rv2970c), 
were expressed in pQE-30 expression vector, purified and their sero-diagnostic efficacy was evaluated 
in an unblinded manner using dot-blot and ELISA methods. The sensitivity and specificity of these 
novel antigens were compared with commercially available standard esat6 and 38 kDa antigens. 
Bacteriologically confirmed TB patients, non-TB disease controls and healthy individuals were included. 
which are based on novel antigen or novel technology, Area under curve (AUC) of the selected antigens 
were 0.98 (0.98–0.99) for rSS1, 0.88 (0.84–0.92) for rSS2, 0.88 (0.84–0.92) for rSS3, 0.95 (0.93–0.98) 
for rSS4 and 0.99 (0.98–1.0) for rSS5. Receiver operative characteristic (ROC) curve showed highly 
significant difference between TB and healthy subjects (p = <0.001). These initial findings, show that 
the recombinant antigens rSS1, rSS4 and rSS5 could be used as highly potential biomarkers for the 
serological diagnosis of active TB.
Tuberculosis (TB) still remains as a major health problem in the developing countries and is rated as the number 
one killer infectious disease. World Health Organization (WHO) estimated 9.6 million new cases and more than 
1.5 million deaths annually worldwide and India has the world’s largest tuberculosis epidemics1. The biggest hur-
dle in the control and timely management of tuberculosis is non-availability of rapid, accurate and cost-effective 
test. In remote areas, TB diagnostics are dependent on the microscopic observation of acid-fast bacilli (AFB) 
in the clinical samples or by bacteriological culture analysis. Although, AFB-smear staining allows rapid and 
cost-effective diagnosis of tuberculosis but it has comparatively low sensitivity, especially in children and 
immuno-compromised patients. The current nucleic acid amplification based tests (NAAT) such as Polymerase 
Chain Reaction (PCR); Xpert MTB/Rif assay; and Line Probe Assay (LPA) are rapid and sensitive but are expen-
sive. A recently held international TB consortium meeting at New Delhi, outlined the urgent need for newer and 
better point-of care tests.
The serological tests have been an attractive diagnostic tool due to their convenience, rapidity and easy imple-
mentation in the national programmes. These tests have contributed significant role in the early diagnosis and 
management of several infectious diseases including Human Immunodeficiency Virus (HIV), hepatitis A, B, 
C, E, Leishmaniasis, malaria etc. However, previous attempts to diagnose TB by serology have met with limited 
success due to low sensitivity and specificity2,3. Hence, WHO banned these serological tests in 2011 and later 
on in 2012 Government of India also banned import manufacturing and sale of these kits3,4. Therefore rapid, 
inexpensive and accurate antibody based tests for TB diagnosis are urgently required5. Earlier, we had reported 
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few differentially expressed proteins that were over expressed during the active disease and development of drug 
resistance in-vivo6. Through bioinformatics analysis, we selected five potential proteins based on their antigenic-
ity. In the present study, we further evaluated these antigens for their diagnostic potential by dot-blot and enzyme 
linked immuno-sorbent assay (ELISA) in various patient and control groups.
Results
Cloning, expression and purification of mycobacterial antigens. The five novel proteins as 
described in the material and method section have been named as rSS1 (Rv2145c), rSS2 (Rv0164), rSS3 (Rv1437), 
rSS4 (Rv1827) and rSS5 (Rv2970c) and a patent has been filed (1752/DEL/2008). The nucleotide sequences of the 
amplicons were analysed and submitted to GenBank under accession number KC147003, KC147004, KC147005, 
KC147006 and KC147008, respectively. To generate recombinant antigens, PCR amplification of target genes 
from genomic DNA of the Mtb clinical isolates7, was carried out using gene specific primers (Table 1). All the 
selected genes were successfully amplified with product size of 783 bp (rSS1), 458 bp (rSS2), 1239 bp (rSS3), 489 bp 
(rSS4) and 1131 bp (rSS5), respectively with appropriate restriction sites (Fig. 1A). The products were cloned 
and desired proteins were expressed in expression vector as detailed in method section. All recombinant pro-
teins were purified by Ni2+-NTA affinity chromatography under denaturing conditions from inclusion bodies 
except the rSS4 protein which was purified under native condition. The purity (> 96%) of N-terminal His-tagged 
recombinant proteins was analysed by SDS-PAGE (Fig. 1B). The observed molecular weights of rSS1, rSS2, rSS3, 
rSS4 and rSS5 proteins were approximately 28 kDa, 18 kDa, 42 kDa, 17 kDa and 42 kDa, respectively. The yield of 
purified recombinant proteins were 3 g (rSS1), 0.7 g (rSS2), 1 g (rSS3), 0.3 g (rSS4) and 0.28 g (rSS5) per litre of the 
bacterial culture.
Detection of antibody response against five antigens by immunoblot assay. The immune 
reactivity of five individual proteins was optimized and used to check diagnostic potential in serum samples 
of different patient groups using dot-blot assay. Two standard proteins (esat6 and 38 kDa) were kind gift from 
Prof. VK Chaudhary. The minimum detection concentrations of the purified antigens were found to be 5 ng 
(rSS1), 10 ng (rSS2), 12.5 ng (rSS3), 10 ng (rSS4), 10 ng (rSS5), 10 ng (38 kDa Ag) and 10 ng (esat6 Ag) of the 
antigens at 1:200 serum dilution in dot-blot assay. The clinical and laboratory characteristics of the TB patients 
and healthy controls (HC) included in the study are summarized in Table 2. A total of 250 subjects were included 
in this study. Of these, 140 were culture confirmed tuberculosis patients [111 pulmonary tuberculosis (PTB) 
and 29 extra-pulmonary tuberculosis (EPTB)] and 110 controls [60 non-tuberculosis-diseased controls (DC) 
and 50 healthy controls (HC)]. Of the 111 PTB patients, 15 were HIV-positive and 96 HIV-negative. Among 
the EPTB patients, five were HIV positive and 15 HIV-negative. Of the 250 subjects 81 (32.4%) had Bacillus 
Calmette-Guérin (BCG) vaccination with discernible scar and 169 (67.6%) had no vaccination/no discernible 
scar. Eighty patients (57.1%) were Mantoux/tuberculin skin test (TST) positive positive, while 170 (42.9%) were 
Mantoux test negative. The control sera (DC plus HC) were included for the assessment of the specificity of 
selected five proteins in ELISA and dot-blots assay. Of which, 60 subjects had diseases other than tuberculosis, 
while 50 were HC (with no known past history of TB and TST negative). Eighteen (30%) DC and 14 (28%) HC 
gave history of M. bovis BCG vaccination and were verified by scar. The sera were tested parallally using each 
recombinant antigen and the results are shown in Tables (3 and 4).
Dot-blot screening of recombinant antigens for TB diagnosis using dot-blot assay. The anti-
body response to the novel antigens was visually analysed (Fig. 2) and results were compared with gold standard 
MGITTM 960 culture for sensitivity calculation. The recombinant esat6 and 38 kDa Ag proteins were used as 
reference antigens. The sensitivity and specificity of esat6 and 38 kDa  antigens ranged between 72.4% to 94% and 
54.5% to 66.4% respectively. The pooled sensitivity of 38 kDa Ag in PTB, EPTB, MDR-TB cases was 85.6%, 86.2% 
94%, while that of esat6 was 85.6%, 72.4%, and 90% respectively. However, in comparison to the reference anti-
gens, the overall performance of our five antigens was much superior. The rSS1, rSS2, rSS3, rSS4, rSS5 antigens 
showed superior sensitivity and specificity both ranging from 86.2% to 99.1% and 89.1% to 100%, respectively. 
S. No. Gene(s) Plasmid Cloning vector (cloning sites) Primers used for amplification
1 rSS1 pQE30 pQE-SS1 F 5′-CGGGATCCATGCCGCTTACACCTGCC-3′ 
(BamHI & HindIII) R 5′ -CCCAAGCTTCTAGTTTTTGCCCCGGTTGAA-3′ 
2 rSS2 pQE30 pQE-SS2 F 5′ -CGGGATCCATGACGGCAATCTCGTGCTC-3′ 
(BamHI & HindIII) R 5′ -CCCAAGCTTTTAGCTGGCCGCCAGCTG-3′ 
3 rSS3 pQE30 pQE-SS3 F 5′ -CGGGATCCATGAGCGTTGCAAACCTCAAG-3′ 
(BamHI & HindIII) R 5′ -CCCAAGCTTTCACAAAACTCCTCCGGTTGG-3′ 
4 rSS4 pQE30 pQE-SS4 F 5′ -CGGGATCCGTG ACG GAC ATG AAC CCG GA-3′ 
(BamHI & HindIII) R 5′ -CCCAAGCTTTCA CGG GCC CCC GGT ACT-3′ 
5 rSS5 pQE30 pQE30-SS5 F 5′ -CGGGATCCATGACCAAGAGTCTGCCAGG-3
(BamHI & HindIII) R 5′ -CCCAAGCTT#TCAAACCCGGCTAAGGTGC-3
Table 1.  Vectors and primers used for cloning of the five novel proteins of Mycobacterium tuberculosis 
(Mtb) named as rSS1, rSS2, rSS3, rSS4 and rSS5. Nucleotide sequences recognised by the restriction enzyme 
used for cloning are underlined.
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The detailed sensitivity and specificity values of each antigen are given in Table (3). In PTB cases, the sensitiv-
ity of these antigens ranged between 99.1% and 93.7% and specificity in various control groups was between 
89.1% and 100%. Interestingly, the rSS1, rSS4 and rSS5 antigens showed 100% sensitivity in HIV-PTB cases 
(see Supplementary Table 1). In EPTB cases also, the pooled sensitivity and specificity were very high (Table 3). 
Antigens rSS1, rSS2, rSS4 and rSS5 showed 100% sensitivity in HIV-EPTB cases and smear positive EPTB cases 
(Supplementary Table 1). In Mantoux positive TB cases, 100% (8/8) sensitivity was observed for rSS5, rSS4 and 
rSS1 antigens followed by 87.5% for rSS2, rSS3, Ag38 kDa and esat6 antigens (Supplementary Table 2). In smear 
negative culture positive cases, antigen rSS5 showed maximum sensitivity of 96.0%. The sensitivity and specificity 
rates of the 5 antigens by dot-blot assay, in MDR-TB cases were 100% while sensitivity of 38 kDa Ag and esat6 Ag 
were found 94% and 90% respectively (Table 3 and Supplementary Table 3).
ELISA screening of purified recombinant antigens for TB diagnosis using ELISA test. The opti-
mum concentration of recombinant antigen yielding high specificity was determined at 25 ng/well for rSS1 and 
rSS5, 50 ng/well for rSS2, rSS3, rSS4, 38 kDa Ag, esat6 Ag and the serum dilutions of primary and secondary 
conjugated antibodies were found to be 1:50 and 1:15000, respectively. Using these dilutions all of the 250 serum 
samples (Table 2) were analysed by indirect ELISA. The cut-off value (Mean ± 2 SD) of the ELISA was determined 
by area under curve (AUC) from 140 TB patient serum samples and 110 HC and DC serum samples (Fig. 3). The 
cut-off values were 0.597 for rSS1, 0.489 for rSS2, 0.540 for rSS3, 0.411 for rSS4, 0.410 for rSS5, 0.57 for 38 kDa 
Ag and 0.56 for esat6 Ag. The AUC were 0.98 (0.98–0.99) for rSS1, 0.88 (0.84–0.92 for rSS2, 0.88 (0.84–0.92) for 
rSS3, 0.95 (0.93–0.98) for rSS4, 0.99 (0.98–1.0) for rSS5 0.90(0.88–0.92) for 38 kDa Ag and 0.81(0.79–0.83) for 
esat6 Ag (Fig. 4).
The highest sensitivity and specificity values for these recombinant antigens were 96.5% & 98.2% for rSS5, 
96.4% & 97.3% for rSS1, 73% & 87.3% for rSS2, 75.9% & 86.4% for rSS3, 91.9% and 94.5% for rSS4, respec-
tively (Table 4). The overall sensitivity of esat6 & 38 kDa Ag was 81.3% and 91.25%, while specificity was 70.9% 
and 60.9% respectively. There was a clear difference in the antibody levels observed in healthy controls vs TB 
patients (PrSS5 < 0.001, PrSS1 < 0.001, PrSS4 < 0.001, PrSS2 < 0.001 and PrSS3 < 0.001, respectively) (Table 4; Fig. 4), 
However, rSS5, rSS1 and rSS4 antigens showed very good activity over other antigens in MDR-TB cases. The 
pooled sensitivity rates in PTB cases by ELISA for antigens rSS1, rSS2, rSS3, rSS4 and rSS5 were between 73.0% 
to 96.4%, (Supplementary Table 4). In EPTB cases, the highest sensitivity (96.5%) and specificity (98.2%) was 
shown by rSS5, followed by 89.7% & 97.3% for rSS1, 89.7% & 94.5% for rSS4, 89.7% & 70.9% for esat6 Ag, 89.7% 
& 60.9% for 38 kDa Ag, 75.9% & 86.7% for rSS3, 69.0% & 87.3% for rSS2 (Fig. 4 and Supplementary Table 5). 
The sensitivity and specificity of five antigens in the MDR-TB patients are given in Supplementary Table (6). In 
comparison to reference antigens, our three antigens (rSS1, rSS4, rSS5) showed extraordinary performance in 
Figure 1. Gene amplification, cloning, expression and purification . (A) Agarose gel electrophoresis for PCR 
products. Lane M, 1 kb DNA Molecular-size marker; lane 1, 2: amplification of respective genes -rSS1 (783 bp), 
rSS2 (468 bp), rSS3 (489 bp), rSS4 (1239 bp), and rSS5 (1131 bp) from M. tuberculosis clinical isolates. lane 3 is 
negative control. (B) SDS-PAGE analyses of purified recombinant proteins (rSS1, rSS2, SS3, rSS4 and rSS5). 
Proteins were visualized with Coomassie brilliant blue staining. Abbreviations: WCL: Whole Cell Lysate, FT: 
Flow Through, P: Purified Protein, M: Marker (Protein).
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PTB cases (Supplementary Table 4). In EPTB cases, only rSS5 antigen showed very high sensitivity (Fig. 4 and 
Supplementary Table 5).
Discussion
Rapid and accurate diagnosis of tuberculosis is crucial to facilitate early treatment initiation, reducing disease 
transmission and preventing emergence of drug resistant strains. The currently used methods are either insensi-
tive, time consuming, costly or require high technical skill and laboratory infrastructure. In search of rapid and 
cost-effective diagnosis of tuberculosis, serological test have been considered an attractive option. In recent past 
decades, a variety of serological assays have been developed such as latex agglutination, ELISA, indirect immuno-
fluorescence and rapid immunochromatographic tests8–11. The rapid serological tests have successfully been used 
to combat several infectious diseases like malaria, leishmaniasis, HIV, hepatitis viral infections etc. to name a few. 
These serological tests, if developed successfully for tuberculosis, will have an additional advantage over all other 
currently used tests, specially in patients who are unable to produce sputum (such as children and HIV/AIDS 
patients) and patients with EPTB. These serological tests will also have potential to develop point of care (POC) 






Gender HIV status BCG Vaccination Mantoux test Smear
MGIT 
Culture (%) MDR (%)Male (%)
Female 




(%) Pos (%) Neg (%)
1 PTB (n = 111) 35.0 ± 15.2 63 (56.8) 48 (43.2) 15 (13.5) 96 (86.5) 42 (37.8) 69 (62.2) 68 (61.3) 43 (38.7) 72 (64.9) 39 (35.1) 111 (100) 46 (41.4)
2 EPTB (n = 29) 31.0 ± 16.1 15 (51.7) 14 (48.3) 5 (17.2) 24 (82.8) 10 (34.5) 19 (65.5) 11 (37.9) 18 (62.1) 4 (13.8) 25 (86.2) 29 (100) 4 (13.8)





31.4 ± 14.6 34 (56.7) 26 (43.3) 20 (33.3) 40 (66.7) 18 (30.0) 42 (70.0) — 60 (100) 0 60 (100) 0 0
Total 250 31.8 ± 14.8 142 (56.8) 108 (43.2) 40 (16.0) 210 (84.0) 84 (33.6) 166 (66.4) 79 (31.6) 171 (68.4) 76 (30.4) 174 (69.6) 140 (56.0) 50 (20.0)
Table 2.  Detailed clinical and demographical profile of subjects (N = 250) included in the study.
Sensitivity [n (%; 95% CI)] Specificity [n (%; 95% CI)] PPV (%) NPV (%) LRP (95% CI) DA %, (95% CI)
PTB cases (n = 111)
rSS5 (Rv2970c) 110/111 (99.1%; 95.1, 99.8) 108/110 (98.2%; 93.6, 99.6) 98.2% 99.1% 54.5 (20.4–145.2) 98.6% (96.1, 99.5)
rSS1 (Rv2145c) 110/111 (99.1%; 95.1, 99.8) 110/110 (100%; 96.6, 100) 100% 99.1% − 99.5% (97.5, 99.9)
rSS4 (Rv1827) 109/111 (98.2%; 93.7, 99.5) 103/110 (93.6%; 87.4, 96.9) 94.0% 98.1% 15.4 (11.6–20.4) 95.9% (92.4, 97.8)
rSS2 (Rv0164) 107/111 (96.4%; 91.1, 98.6) 102/110 (92.7%; 86.3, 96.3) 93.0% 96.2% 13.2 (10.4–16.9) 94.6% (90.7, 96.9)
rSS3 (Rv1437) 104/111 (93.7%; 87.5, 96.9) 98/110 (89.1%; 81.9, 93.6) 89.7% 93.3% 8.6 (7.3–10.1) 91.4% (87.0, 94.4)
Esat6 Ag 95/111 (85.6%; 77.9, 90.9 ) 73/110 (66.4%; 57.1, 74.51) 72.0% 82.0% 2.5 (2.4–2.7) 76.0% (70.0, 81.2)
38 kDa Ag 95/11116 (85.6%; 77.9, 90.9) 60/110 (54.5%; 45.2, 63.5) 65.5% 78.9% 1.9 (1.8–2.0) 70.1% (63.8, 75.8)
EPTB cases (n = 29)
rSS5 (Rv2970c) 28/29 (96.5%; 82.8, 99.4) 108/110 (98.2%; 93.6, 99.6) 93.3% 99.1% 53.1 (19.9–141.8) 97.8% (93.8, 99.3)
rSS1 (Rv2145c) 27/29 (93.1%; 78.0, 98.1) 110/110 (100%; 96.6, 100) 100% 98.2% — 98.6% (94.9, 99.6)
rSS4 (Rv1827) 27/29 (93.1%; 78.0, 98.1) 103/110 (93.6%; 87.4, 96.9) 79.4% 98.1% 14.6 (11.0–19.5) 93.5% (88.1, 96.6)
rSS2 (Rv0164) 25/29 (86.2%; 69.4, 94.5) 102/110 (92.7%; 86.3, 96.3) 75.8% 96.2% 11.8 (9.2–15.3) 91.4% (85.5, 95.0)
rSS3 (Rv1437) 26/29 (89.7%; 73.6, 96.4) 98/110 (89.1%; 81.9, 93.6) 68.4% 97.0% 8.2 (6.9–9.8) 89.2% (83.0, 93.3)
Esat6 Ag 21/29 (72.4%; 54.3, 85.3) 73/110 (66.4%; 57.1, 74.51) 36.2% 90.1% 2.1 (2.0–2.3) 67.6 (59.5–74.8)
38 kDa Ag 25/29 (86.2%; 69.4, 94.5) 60/110 (54.5%; 45.2, 63.5) 33.4% 93.7% 2.0 (1.8–2.0) 61.1% (52.8, 68.8)
MDR-TB Cases [(n = 50)
rSS5 (Rv2970c) 50/50 (100%; 92.9, 100) 108/110 (98.2%; 93.6, 99.6) 96.1% 100% 55.0 (20.6–146.5) 98.7% (95.6, 99.7)
rSS1 (Rv2145c) 50/50 (100%; 92.9, 100) 110/110 (100%; 96.6, 100) 100% 100% — 100% (97.7, 100)
rSS4 (Rv1827) 50/50 (100%; 92.9, 100) 103/110 (93.6%; 87.4, 96.9) 87.7% 100% 15.7 (11.9–20.8) 95.6% (91.2, 97.9)
rSS2 (Rv0164) 50/50 (100%; 92.9, 100) 102/110 (92.7%; 86.3, 96.3) 86.2% 100% 13.7 (10.8–17.6) 95.0% (90.4, 97.4)
rSS3 (Rv1437) 50/50 (100%; 92.9, 100) 98/110 (89.1%; 81.9, 93.6) 80.6% 100% 9.2 (7.8–10.8) 92.5% (87.3, 95.7)
Esat6 Ag 45/50 (90.0%;78.6, 95.6 ) 73/110 (66.4%; 57.1, 74.51) 54.9% 93.6% 2.7 (2.5–2.8) 73.7% (66.4, 79.9)
38 kDa Ag 47/50 (94.0%;83.8, 97.9) 60/110 (54.5%; 45.2, 63.5) 48.4% 95.2% 2.1 (2.0–2.2) 66.9% (59.3, 73.7)
Table 3.  Sensitivity and specificity of 5 novel recombinant antigens by dot-blot assay [PTB = 111, 
EPTB = 29 and controls = 110]. Pos: Positive, Neg: Negative, CI: Confidence interval, PPV: Positive predictive 
value, NPV: Negative predictive value, LRP: likelihood ratio for positive test, DA: Diagnostic accuracy. *Also see 
supplementary file 1.
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To develope the serological tests, for the diagnosis of tuberculosis, researchers have used both crude as well 
recombinant antigens8,9,12. The performance of these tests has been evaluated using single as well as cocktail of 
multiple antigens13–16. The most commonly used and commercially available antigens have been the esat6 and 
Mtb 38 kDa recombinant antigens. However, this antigen showed sensitivity of only 47% and specificity of 94% 
in smear positive patients, in studies carried out earlier13. In present study also the performance of this antigen 
was far inferior to our newly described antigens. Another recombinant protein used earlier was malate synthase 
and MPT51. At laboratory level, the malate synthase showed the specificity of 98% and sensitivity of 73% in spu-
tum smear positive patients17,18. The MPT51 protein showed poor sensitivity rates of 59% in HIV-negative TB 
patients and 58% in HIV-TB patients19,20. Its sensitivity and specificity rates reported by others were between 74 
to 80% and 34 to 74% respectively21,22. Recently, Feng et al.23 reported that a polyprotein comprising of 38 kDa and 
MPT64 are suitable for diagnosing active tuberculosis with sensitivity and specificity of 70.4% and 91.5% respec-
tively. A recombinant TbF6 antigen was generated by fusion of four distinct antigens (38 kDa, CFP-10, MTB8, 
and MTB48) in a single protein. However, its sensitivity in sputum smear positive patients remained below 70% 
only17,19,24,25. These and several other antigens were used to develop commercial ELISA and rapid diagnostic test 
(RDT) kits, despite giving low sensitivity and specificity3. Prompted by concerns raised by academia in 2008, the 
WHO special programme for Research and Training in Tropical Diseases (TDR) performed an evaluation of 19 
commercially available TB diagnostic kits26. The meta-analysis of these kit evaluation results showed the sensi-
tivity of 1% to 60% and specificity of 53% to 99% under field conditions. Several other systematic reviews and 
original evaluation studies also showed similar findings3–5,17,27.
Our antigens provided outstanding sensitivity and specificity, not reported earlier. This could most likely be 
due to the fact that in all previous studies recombinant antigens were prepared from the laboratory maintained 
H37Rv strain, while in our study we used a well characterized but fresh clinical isolate which developed in-vivo 
multidrug resistance6,7. We consider that this was a major turning point in the development of these antigens. It 
has been documented that expression levels as well as the characters of proteins expressed by the H37Ra, H37Rv, 
and clinical isolates are significantly different28. It is also important to mention that the diagnostic potential of the 
five recombinant proteins which we used in this study, has never been explored on such a scale for the diagnosis 
of tuberculosis29.
For comparison we included esat6 and 38 kDa antigens as reference proteins. In fact while comparing the 
sensitivity and specificity of our antigens with these two reference antigens, we found that antigen rSS1, rSS4 
and rSS5 are highly significantly superior to the esat6 and 38 kDa Ag or other previously published studies30. In 
comparison to reference antigen (esat6 and 38 kDa Ag), We noticed great difference in the specificity of rSS1, 
rSS2, rSS3, rSS4, rSS5 antigens, though only three antigens (rSS1, rSS4, rSS5) showed significant difference in 
the sensitivity. We found that in previous evaluation studies, several kits were marketed without evaluating the 
Sensitivity [n (%; 95% CI)] Specificity [n (%; 95% CI)] PPV (%) NPV (%) LRP (95% CI) DA%, (95% CI)
PTB cases (n = 111)
rSS5 (Rv2970c) 107/111 (96.4%; 91.1, 98.6) 108/110 (98.2%; 93.6, 99.5) 98.2% 96.4% 53.2 (19.9–141.4) 97.3% (94.2, 98.7)
rSS1 (Rv2145c) 107/111 (96.4%; 91.1, 98.6) 107/110 (97.3%; 92.3, 99.1) 97.3% 96.4% 35.3 (18.4–68.0) 96.8% (93.6, 98.5)
rSS4 (Rv1827) 102/111 (91.9%; 85.3, 95.7) 104/110 (94.5%; 88.6, 97.5) 94.5% 92.0% 16.8 (12.1–23.4) 93.2% (89.1, 95.8)
rSS2 (Rv0164) 81/111 (73.0%; 64.0, 80.4) 96/110 (87.3%; 79.8, 92.3) 85.3% 76.2% 5.7 (4.9–6.6) 80.1% (74.3, 84.8)
rSS3 (Rv1437) 82/111 (73.9%; 65.0, 81.1) 95/110 (86.7%; 78.7, 91.6) 84.5% 76.6% 5.4 (4.7–6.2) 80.1% (74.3, 84.8)
Esat6 Ag 81/111 (72.97%;64.0, 80.4) 78/110 (70.9%; 61.8, 78.6) 71.7% 72.2 2.5 (2.3–2.7) 71.9% (65.7–77.5)
38 kDa Ag 103/11 (92.8%;86.4, 96.3) 67/110 (60.9%; 51.6, 69.5) 70.5% 89.3% 2.4 (2.3–2.5) 76.9% (70.9, 82.0)
EPTB cases (n = 29)
rSS5 (Rv2970c) 28/29 (96.5%; 82.8, 99.4) 108/110 (98.2%; 93.6, 99.5) 93.3% 99.1% 53.1 (19.9–141.8) 97.8% (93.8, 99.3)
rSS1 (Rv2145c) 26/29 (89.7%; 73.6, 96.4) 107/110 (97.3%; 92.3, 99.1) 89.7% 97.3% 32.9 (17.0–63.7) 95.7% (90.9, 98.0)
rSS4 (Rv1827) 26/29 (89.7%; 73.6, 96.4) 104/110(94.5%; 88.6, 97.5) 81.2% 97.2% 16.4 (11.7–23.0) 93.5% (88.1, 96.6)
rSS2 (Rv0164) 20/29 (69.0%; 50.8, 82.7) 96/110 (87.3%; 79.8, 92.3) 58.8% 91.4% 5.4 (4.5–6.5) 83.4% (76.4, 88.7)
rSS3 (Rv1437) 22/29 (75.9%; 57.9, 87.8) 95/110 (86.7%; 78.7, 91.6) 59.5% 93.1% 5.6 (4.7–6.5) 84.2% (77.2, 89.3)
Esat6 Ag 26/29 (89.7%; 73.6, 96.4) 78/110 (70.9%; 61.8, 78.6) 44.8% 96.3% 3.1 (2.9–3.3) 74.8% (67.8, 81.3)
38 kDa Ag 26/29 (89.7%; 73.6, 96.4) 67/110 (60.9%; 51.6, 69.5) 37.7% 95.7% 2.3 (2.2–2.4) 66.9% (58.7, 74.2)
MDR-TB Cases [(n = 50)
rSS5 (Rv2970c) 50/50 (100%; 92.9, 100) 108/110 (98.2%; 93.6, 99.5) 96.1% 100% 55.0 (20.6–146.5) 98.7% (95.6, 99.6)
rSS1 (Rv2145c) 50/50 (100%; 92.9, 100) 107/110 (97.3%; 92.3, 99.1) 94.3% 100% 37.7 (19.1–70.5) 98.1% (94.6, 99.4)
rSS4 (Rv1827) 50/50 (100%; 92.9, 100) 104/110(94.5%; 88.6, 97.5) 89.3% 100% 18.3 (13.2–25.4) 96.2% (92.1, 98.3)
rSS2 (Rv0164) 38/50 (76.0%; 62.6, 85.7) 96/110 (87.3%; 79.8, 92.3) 73.1% 88.9% 6.0 (5.1–7.0) 83.7% (77.2, 88.7)
rSS3 (Rv1437) 41/50 (82.0%; 69.2, 90.2) 95/110 (86.7%; 78.7, 91.6) 73.2% 91.3% 6.0 (5.2–6.9) 85.0% (78.6, 89.7)
Esat6 Ag 33/50 (66.0%; 52.1, 77.6) 78/110 (70.9%; 61.8, 78.6) 50.8% 82.1% 2.3 (2.1–2.5) 69.4% (61.8, 76.0)
38 kDa Ag 47/50 (94.0%; 83.8, 97.9) 67/110 (60.9%; 51.6, 69.5) 55.2% 95.7% 2.4 (2.3–2.5) 71.2% (63.8, 77.7)
Table 4.  Sensitivity and specificity of 5 novel recombinant antigens by ELISA test [PTB = 111, EPTB = 29 
and control = 110]. Pos: Positive, Neg: Negative, CI: Confidence interval, PPV: Positive predictive value, 
NPV: Negative predictive value, LRP: likelihood ratio for positive test, DA: Diagnostic accuracy. *Also see 
supplementary file 1.
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specificity of these antigens on disease controls (i.e. HIV, leishmaniasis, toxoplasmosis, cancer, and diabetes) in 
whom these commercial kits failed badly. However, we have included not only healthy controls but also various 
disease controls in this study. Most importantly, three recombinant antigens (rSS5, rSS1 and rSS4) showed very 
high utility in MDR-TB cases. This is an important finding of our study and we propose that these three antigens 
can be used not only for diagnosis of TB but can help in the ruling out the disease severity. We found higher sen-
sitivity of all these antigen in dot-blot as compared to ELISA. The reason for this could be higher cut-off taken in 
ELISA while in dot-blot any visible dot was considered as positive. Likelihood ratio (LR) of positive test is also an 
important statistical method to better evaluate the diagnostic test. In our study, LR of positive test values was very 
high (ranging from 5.5–53.5). The areas under the ROC curve (AUC) showed an excellent diagnostic efficacy of 
our recombinant antigens (Table 4). The data also shows that our antigens do not cross react with M. bovis (BCG) 
vaccine. The antigen rSS4 is conserved hypothetical protein which stimulates T-cell response in the host. The rSS5 
is a probable lipase/esterase LipN while rSS2 is an essential hypothetical protein29. The rSS3 is a phosphoglycerate 
kinase6 involved in the second phase of glycolysis and to best of our knowledge, none of these antigen has been 
used for serodiagnosis of tuberculosis in India. Even though, the study showed very high utility of three antigen 
in the detection of active TB, but study had some limitations; all antigens were not tested with other disease con-
trol groups i.e. house hold contacts, latent TB, other pulmonary diseases such as asthma, bronchitis, pneumonia, 
allergies and also need to be evaluated in different geographical regions of world before commercialization.
Therefore, we can conclude that these results convince us that at least 3 of these five antigens can successfully 
be used for screening all the suspected cases of active tuberculosis, though not for confirming the diagnosis. We 
are in process of developing semi-quantitative rapid diagnostics tests (RDTs) in a way that these biomarkers can 
be used to detect and predicting tuberculosis, by measuring the high expression of these antigens. We strongly 
believe that rapid tests developed from these antigens can meet an urgent requirement of triage test for all forms 
of tuberculosis.
Figure 2. Dot-blot results showing the reactivity of purified recombinant proteins rSS1, rSS2, rSS3, rSS4, 
rSS5, Ag38 kDa and esat6 with serum samples from patients with  extra-pulmonary tuberculosis (EPTB) 
pulmonary tuberculosis (PTB) HIV-TB, MDR-TB as well as from  healthy controls (HC) and diseases 
controls (DC). Specific binding of the antigen to its antibody is indicated by a dark spot.
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Material and Methods
Cloning of the over-expressing genes. To express the desired antigens, the genomic DNA of Mtb clini-
cal isolates (AIIMS/LM/SS/TB-1920/06) was used as the template for PCR reactions using gene specific primers 
(Table 1) as reported earlier7. The conditions for PCR were as follows: a 50 μ l PCR mixture were comprised of 
10 mM Tris-Cl (pH 8.2); 50 mM MgCl2, deoxynucleoside triphosphate (200 μ M each), 1.0 U of Taq DNA poly-
merase, 0.5 μ l of each primer and 100 ng of genomic DNA. The reaction mixture was subjected to initial denatur-
ation at 94 °C for 10 min followed by 30 amplification cycles of 94 °C for 1 min, annealing (rSS1 at 53 °C; rSS2 at 
64 °C; rSS3 at 58 °C; rSS4 at 65 °C and rSS5 at 58 °C) for 45 sec, amplification at 72 °C for 45 sec and final extension 
at 72 °C for 10 min in a PTC-100 thermal cycler (MJ Research, USA).
Purified PCR product of each gene was cloned in to the pGEMT easy cloning vector and transformed in E. 
coli JM109 strain as per manufacturer instruction and plated out in appropriate antibiotic containing plates. 
Blue-white selection method was used for clones screening. Plasmids were extracted from randomly selected 
clones and subjected to restriction digestion by HindIII and BamHI restriction enzymes for clone confirmation. 
Gel purified inserts were sub-cloned into pQE-30 expression vector and transformed in E. coli M15 strain. All 
recombinant clones were selected in 100 μ g/ml ampicillin and 50 μ g/ml kanamycin containing Luria-Bertani (LB) 
agar plate. Plasmids were again extracted from all selected clones and presence of insert was confirmed by DNA 
sequencing.
Recombinant clones were cultured overnight at 37 °C in LB broth containing appropriate antibiotics. 
Overnight grown culture was inoculated into fresh LB medium containing antibiotics and incubated at 37 °C 
with shaking at 225 rpm until OD (600 nm) reached at 0.6. Thereafter, protein expression was induced by 1 mM 
isopropyl-β -D-1-thiogalactopyranoside (IPTG) at the mid-exponential phase of growth. Cultures were grown for 
an additional 4 h with shaking at 37 °C for proteins expression. Bacterial pellets were harvested by centrifugation 
at 12,000 rpm for 5 min and stored at − 80 °C until use. Pellets were re-suspended in lysis buffer (20 mM Tris (pH-
8.0), 150 mM NaCl and 1 mM phenylmethylsulfonyl fluoride (PMSF) and disrupted by sonication followed by 
centrifugation at 12000 rpm for 30 min at 4 °C. Recombinant proteins were purified under native and denaturing 
conditions by using Ni2+ NTA metal-ion-affinity chromatography as per manufacturer’s instructions (Qiagen, 
Germany). Purity level were analysed through sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Figure 3. Scatter plots of ELISA results using our novel recombinant antigens and the reference antigens. 
Recombinant antigens assayed are rSS1, rSS2, rSS3, rSS4, rSS5, Esat-6 and 38 kDa Ag). The serum samples used 
were from of healthy controls (HC), diseased controls (DC), tuberculosis patient (PTB, EPTB, HIV-TB) and 
MDR-TB. The scatter plot indicates the antibody level per subject analysed. A dotted horizontal line is included 
to show the cut-off value for individual antigen.
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(SDS-PAGE). Purified proteins were dialyzed against 20 mM Tris, pH 8.0, and concentrated using Amicon Ultra 
10 kDa/3 kDa – cut off centrifugal filters (Millipore, India). The concentration of purified proteins was quantified 
by Bradford protein assay (Bio-Rad, USA).
Recombinant esat6 Ag and 38 kDa Ag proteins. The recombinant esat6 Ag and 38 kDa Ag were 
kind gifts from CIIDRET, University of Delhi South Campus, New Delhi. The preparation of esat6 is described 
previously31,32. The 38 kDa antigen was produced as N-terminal deca-histidine-tagged protein using T7 
promoter-based expression system as described previously for hexa-histidine-tagged 38 kDa33.
Study population and serum sample collection. The study was conducted from 2009–2015. 
Institutional ethics committee of the All India Institute of Medical Sciences (AIIMS), New Delhi approved the 
study (Ref No. T-9/31.7.2009). The participants were included after informed and written consent to participate 
in this study. A total of 250 subjects [TB patients (n = 140), DC (n = 60) and HC (n = 50)] were eligible for the 
evaluation of the diagnostic performance of five recombinant antigens. Of 140 culture confirmed TB cases, 111 
were PTB PTB cases and 29 samples were from EPTB cases included 50 MDR-TB drug susceptibility (DST) con-
firmed cases (n = 46 PTB, n = 4 EPTB). The selection criteria for PTB cases was; similar to the diagnostic rec-
ommendation defined by Revised National Tuberculosis Control Program (RNTCP)34. In brief: was defined of a 
patient, presented with cough and fever > 2 weeks, mysterious weight loss, fatigue, past history of patients/fam-
ily members with TB or those diagnosed as having TB by the clinician and advised to receive full course of TB 
treatment. The medical history of the patients was obtained before collection of the blood sample and details of 
other investigations including chest x-ray. and other laboratory findings were recorded from the patient file. The 
clinically diagnosed case of TB, involving specimens from lung parenchyma or the tracheobronchial tree were 
classified as PTB, while clinical samples linking to organs other than the lungs, e.g. pleura, lymph nodes, abdo-
men, genitourinary tract, skin, joints and bones, meninges were classified as EPTB cases. The clinical isolates 
obtained from PTB and EPTB cases were subjected to first line drug susceptibility testing; those isolates showing 
resistance to isoniazid and rifampicin were classified as MDR-TB cases. Only three types of patients with HIV, 
Toxoplasmosis, Leishmaniasis (confirmed by commercial ICTs/ELISA based test) were included in the disease 
control group. The TB status in the participants of diseased group was confirmed by MGIT960 culture. Other 
patients with disease such as hepatitis, cancer, diabetes and other autoimmune diseases were excluded. The 
blood samples of all TB negative participants (healthy volunteers) were selected from the individuals with no 
sign/history of TB and who tested negative by tuberculin skin test (TST). The TST was performed by a trained 
phlebotomist. The 5 TU/0.1 mL tuberculin (Span Diagnostics, Surat, India) was administrated intradermally on 
the volar aspect of the forearm and read after 48–72 hours; an induration ≥ 10 mm was defined as positive. All 
Figure 4. Receiver operative characteristic (ROC) curves of the antibody response against five M. tuberculosis 
recombinant antigens (rSS1, rSS2, rSS3, rSS4, rSS5) with two reference antigens (esat6 and Ag38 kDa) in (a) 
PTB, (b) EPTB and (c) MDR-TB patients and healthy controls.
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serum samples were stored in different aliquots and stored at − 80 °C. Other patients details such as age, gender 
and vaccination and are listed in Table 2.
Western blot and dot-blot Assays. The purified proteins were resolved on 12% SDS-PAGE and trans-
ferred on to nitrocellulose membranes using semi-dry blotting apparatus (Bio-Rad, Hercules USA) following 
manufacturer instructions. For dot-blot, PBS was used as the spotting and dilution buffer for all purified recom-
binant proteins. A dot-blot was x spotted on a nitrocellulose membrane using a Bio-Dot 96-well manifold appa-
ratus (Bio-Rad, Hercules, USA). The 100 μ l of diluted proteins were loaded on each well of the assembled 96-well 
dot-blot apparatus with the final concentration of proteins 25 ng/well. The membrane was blocked with blocking 
buffer (5% skimmed milk in 1x Phosphate Buffer Saline (PBS)) for overnight at 4 °C. Membrane was washed 
5 times with 1x PBST (1xPBS + 0.5% Tween20) and probed with culture confirmed PTB, EPTB or MDR-TB 
patients’ sera (1:200 dilutions in 1xPBS containing 0.25% bovine serum albumin) for 2 hrs at 37 °C. Serum sam-
ples from healthy and disease controls were also tested in the same manner. After Incubation, membrane was 
again washed 5 times with 1x PBST and probed with anti-human IgG (whole molecule) HRP-conjugated anti-
body (Sigma, USA) as the secondary antibody (1:8000 dilutions) for 2 hrs at 37 °C. The membranes were devel-
oped by using 3,3′ -Diaminobenzidine (DAB), (Sigma Aldrich, USA) as substrate through incubation at room 
temp for 30–40 second as substrate for 30–40 sec at RT.
Indirect Enzyme-Linked Immunosorbent Assay (ELISA). Checkerboard titration (CBT) method was 
used for the detection of optimum serum dilution and antigen concentration in ELISA. Ninety-six well flat bot-
tom plates (BD, New Jersey, USA) were coated with purified antigens of 25 ng/well (rSS1 and rSS5) or 50 ng/well 
(rSS2, rSS3, rSS4, esat6 and 38 kDa Ag) in 100 μl/well 0.1 M bicarbonate buffer (pH 9.6) and incubated at 4 °C for 
overnight. Plates were washed 3 times with 1x PBST, blocked with blocking buffer (5% fat free skimmed milk 
in PBS) for two hour at 37 °C and followed by three washing with 1x PBST. Optimum serum dilutions (1:50) 
were added on each well and incubated for 2 h at 37 °C. The plates were again washed three times with PBST and 
then incubated for 2 h with anti-human IgG, whole antibody conjugated with horseradish peroxidase (1:15,000 
dilutions) followed by washing with 1x PBST. Enzyme activity was assayed by incubation for 15 min at 37 °C with 
100 μ l of tetramethylbenzidine (TMB) per well. Reaction was stopped by using 50 μ l of 2N sulfuric acid in each 
well and the OD was taken at 450 nm. All the serum samples were tested in duplicate wells and experiments were 
repeated three times to verify the reproducibility of results. All in-vitro methods were performed in accordance 
with the standard guidelines and institutional regulations and following the manufacturer’s instructions, if a 
commercial equipment, device or kit was used.
Statistical analysis. Data were presented as means and standard deviation (mean ± 2 SD). The cut-off value 
of an ELISA was determined by using receiver operative characteristic (ROC) curve analysis. ROC curves were 
plotted using STATA SE.11.0 (Stata Corp LP, Texas, USA) software. ROC curve describes probability of accuracy 
of the test result at different cut-off values. The individual sample was scored positive, if the OD was above the 
Youden index (YI) value. Sensitivity was determined by dividing the number of positive cases by the total number 
of TB patients. Specificity was determined by dividing the number of negative controls by the total number of 
healthy controls.
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